BCL6 and neoplasm: Thus, SCC7 tumor-bearing C3H mice were randomly divided into four treatment groups: i) control; ii) anti-PDL1 antibody; iii) Bcl6 inhibitor FX1, and iv) combination therapy of FX1 and anti-PDL1 (Fig. 5A).